NASM North American Scientific (MM)

North American Scientific, Inc. (NASDAQ: NASI) today announced that effective May 1, 2008, the Company will operate as NAS Medical, a division of North American Scientific, to reflect the Company�s focus on its medical therapeutic product opportunities. Although the Company will not formally change its corporate name, all product, customer, employee and investor communications will highlight the new NAS Medical name and logos. Consistent with this new emphasis, the Company will change its NASDAQ Listing Symbol to �NASM� from �NASI� effective at the opening of business on May 1, 2008. �Operating under the name NAS Medical more accurately describes for our customers, employees and shareholders the focus we have on better therapy for patients with cancer,� said John Rush, President and CEO. �Our Prospera� brachytherapy seeds for the treatment of prostate cancer, have been responsible for the majority of our revenue growth over the last year. Our new ClearPath� HDR device for the treatment of breast cancer, scheduled to be released for clinical experience in the coming weeks, represents additional potential growth and margin improvement. Market penetration with our medical therapeutic products represent a sizeable future opportunity and will remain the primary focus of the Company.� About North American Scientific North American Scientific is a leader in radiation therapy in the fight against cancer. Its innovative products provide physicians with tools for the treatment of various types of cancers. They include Prospera� brachytherapy seeds and SurTRAK� needles and strands used primarily in the treatment of prostate cancer. In addition, the Company has been gaining clinical experience with its first generation ClearPath� multi-channel catheter breast brachytherapy devices in 2007, and intends to launch the second generation devices in 2008. They are the only such devices approved for both high dose and continuous release, or low dose, radiation treatments. The devices are designed to provide flexible, precise dose conformance and an innovative delivery system that is intended to offer the more advanced form of brachytherapy for the treatment of breast cancer. Please visit www.nasmedical.com for more information. Statements included in this release that are not historical facts may be considered forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company including, but not limited to, the impact of competitive products and pricing, technological changes, changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements, the ability of the Company to successfully directly market and sell its products, uncertainties relating to patent protection and regulatory approval, the stable supply of appropriate isotopes, research and development estimates, market opportunities, risks associated with strategic opportunities or acquisitions the Company may pursue and the risk factors included in the Company�s filings with the Securities and Exchange Commission. Any forward-looking statements contained in this news release speak only as of the date of this release, and the Company undertakes no obligation to revise or update any forward-looking statements, whether as a result of new information, future results or otherwise.